Do analysts recommend CPHI or BDTX?

Black Diamond Therapeutics has a consensus price target of $9.83, suggesting a potential upside of 421.66%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Black Diamond Therapeutics 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.73

Do analysts recommend CPHI or ANIX?

Anixa Biosciences has a consensus target price of $8.50, indicating a potential upside of 167.30%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Anixa Biosciences is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Anixa Biosciences 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Do analysts recommend FTLF or CPHI?

FitLife Brands presently has a consensus target price of $21.50, indicating a potential upside of 94.83%. Given FitLife Brands' stronger consensus rating and higher probable upside, equities research analysts plainly believe FitLife Brands is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FitLife Brands 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate SXTC or CPHI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, SXTC or CPHI?

China Pharma has higher revenue and earnings than China SXT Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio China SXT Pharmaceuticals $1.14M 84.32 -$6.20M N/A N/A China Pharma $3.99M 6.05 -$3.08M -$0.55 N/A

China Pharma (CPHI) Competitors

$0.60 -0.03 (-4.64%)

As of 02:28 PM Eastern

Compare

CPHI vs. BDTX, ANIX, FTLF, AADI, and SXTC

Should you buy China Pharma stock or one of its competitors? MarketBeat compares China Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with China Pharma include Black Diamond Therapeutics (BDTX), Anixa Biosciences (ANIX), FitLife Brands (FTLF), Aadi Bioscience (AADI), and China SXT Pharmaceuticals (SXTC). These companies are all part of the "pharmaceutical products" industry.

How does China Pharma compare to Black Diamond Therapeutics?

China Pharma (NYSE:CPHI) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

China Pharma has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.25, meaning that its share price is 225% more volatile than the broader market.

95.5% of Black Diamond Therapeutics shares are held by institutional investors. 6.4% of China Pharma shares are held by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Black Diamond Therapeutics has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. Black Diamond Therapeutics' return on equity of -30.18% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Black Diamond Therapeutics	N/A	-30.18%	-23.91%

Black Diamond Therapeutics has higher revenue and earnings than China Pharma. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	6.05	-$3.08M	-$0.55	N/A
Black Diamond Therapeutics	$70M	1.54	$22.37M	-$0.77	N/A

Black Diamond Therapeutics has a consensus price target of $9.83, suggesting a potential upside of 421.66%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

In the previous week, Black Diamond Therapeutics had 1 more articles in the media than China Pharma. MarketBeat recorded 1 mentions for Black Diamond Therapeutics and 0 mentions for China Pharma. Black Diamond Therapeutics' average media sentiment score of 1.90 beat China Pharma's score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
China Pharma	Neutral
Black Diamond Therapeutics	Very Positive

Summary

Black Diamond Therapeutics beats China Pharma on 14 of the 17 factors compared between the two stocks.

How does China Pharma compare to Anixa Biosciences?

China Pharma (NYSE:CPHI) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

China Pharma has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

Anixa Biosciences has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Anixa Biosciences	N/A	-71.12%	-62.88%

Anixa Biosciences has a consensus target price of $8.50, indicating a potential upside of 167.30%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Anixa Biosciences is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Anixa Biosciences had 5 more articles in the media than China Pharma. MarketBeat recorded 5 mentions for Anixa Biosciences and 0 mentions for China Pharma. Anixa Biosciences' average media sentiment score of 0.57 beat China Pharma's score of 0.00 indicating that Anixa Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
China Pharma	Neutral
Anixa Biosciences	Positive

China Pharma has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	6.05	-$3.08M	-$0.55	N/A
Anixa Biosciences	$210K	515.16	-$10.93M	-$0.31	N/A

29.1% of Anixa Biosciences shares are held by institutional investors. 6.4% of China Pharma shares are held by insiders. Comparatively, 26.4% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Anixa Biosciences beats China Pharma on 10 of the 16 factors compared between the two stocks.

How does China Pharma compare to FitLife Brands?

FitLife Brands (NASDAQ:FTLF) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

FitLife Brands presently has a consensus target price of $21.50, indicating a potential upside of 94.83%. Given FitLife Brands' stronger consensus rating and higher probable upside, equities research analysts plainly believe FitLife Brands is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

2.3% of FitLife Brands shares are owned by institutional investors. 61.7% of FitLife Brands shares are owned by insiders. Comparatively, 6.4% of China Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

FitLife Brands has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market. Comparatively, China Pharma has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

FitLife Brands has a net margin of 6.64% compared to China Pharma's net margin of -85.56%. FitLife Brands' return on equity of 18.31% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FitLife Brands	6.64%	18.31%	8.21%
China Pharma	-85.56%	-63.93%	-31.42%

FitLife Brands has higher revenue and earnings than China Pharma. China Pharma is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$81.46M	1.27	$6.33M	$0.60	18.39
China Pharma	$3.99M	6.05	-$3.08M	-$0.55	N/A

In the previous week, FitLife Brands had 3 more articles in the media than China Pharma. MarketBeat recorded 3 mentions for FitLife Brands and 0 mentions for China Pharma. FitLife Brands' average media sentiment score of 1.60 beat China Pharma's score of 0.00 indicating that FitLife Brands is being referred to more favorably in the media.

Company	Overall Sentiment
FitLife Brands	Very Positive
China Pharma	Neutral

Summary

FitLife Brands beats China Pharma on 14 of the 16 factors compared between the two stocks.

How does China Pharma compare to Aadi Bioscience?

Aadi Bioscience (NASDAQ:AADI) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

52.1% of Aadi Bioscience shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by insiders. Comparatively, 6.4% of China Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

China Pharma has lower revenue, but higher earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	3.78	-$65.76M	-$2.35	N/A
China Pharma	$3.99M	6.05	-$3.08M	-$0.55	N/A

China Pharma has a net margin of -85.56% compared to Aadi Bioscience's net margin of -246.06%. China Pharma's return on equity of -63.93% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
China Pharma	-85.56%	-63.93%	-31.42%

In the previous week, Aadi Bioscience's average media sentiment score of 0.00 equaled China Pharma'saverage media sentiment score.

Company	Overall Sentiment
Aadi Bioscience	Neutral
China Pharma	Neutral

Aadi Bioscience has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, China Pharma has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

Summary

China Pharma beats Aadi Bioscience on 8 of the 11 factors compared between the two stocks.

How does China Pharma compare to China SXT Pharmaceuticals?

China SXT Pharmaceuticals (NASDAQ:SXTC) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

In the previous week, China SXT Pharmaceuticals had 3 more articles in the media than China Pharma. MarketBeat recorded 3 mentions for China SXT Pharmaceuticals and 0 mentions for China Pharma. China SXT Pharmaceuticals' average media sentiment score of 0.96 beat China Pharma's score of 0.00 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
China SXT Pharmaceuticals	Positive
China Pharma	Neutral

China SXT Pharmaceuticals has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China SXT Pharmaceuticals' return on equity of 0.00% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China SXT Pharmaceuticals	N/A	N/A	N/A
China Pharma	-85.56%	-63.93%	-31.42%

China Pharma has higher revenue and earnings than China SXT Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China SXT Pharmaceuticals	$1.14M	84.32	-$6.20M	N/A	N/A
China Pharma	$3.99M	6.05	-$3.08M	-$0.55	N/A

5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Comparatively, 6.4% of China Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

China SXT Pharmaceuticals has a beta of 1.82, suggesting that its stock price is 82% more volatile than the broader market. Comparatively, China Pharma has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market.

Summary

China SXT Pharmaceuticals beats China Pharma on 9 of the 12 factors compared between the two stocks.

Get China Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPHI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPHI vs. The Competition

Export

Metric	China Pharma	Pharmaceutical Industry	Medical Sector	NYSE Exchange
Market Cap	$24.15M	$937.17M	$6.75B	$23.35B
Dividend Yield	N/A	4.84%	2.68%	4.02%
P/E Ratio	-1.08	1.54	26.99	31.17
Price / Sales	6.05	114.41	585.80	20.23
Price / Cash	N/A	22.05	29.22	18.64
Price / Book	0.85	8.57	10.86	4.78
Net Income	-$3.08M	-$3.66M	$3.58B	$1.06B
7 Day Performance	-14.49%	-2.90%	-1.95%	-0.06%
1 Month Performance	-16.60%	-0.06%	3.47%	0.04%
1 Year Performance	-68.47%	35.70%	26.84%	16.83%

China Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPHI China Pharma	N/A	$0.60 -4.6%	N/A	-67.2%	$24.15M	$3.99M	N/A	250	Gap Down
BDTX Black Diamond Therapeutics	4.2366 of 5 stars	$1.88 -1.1%	$9.83 +423.0%	-33.8%	$108.87M	$70M	N/A	90	Positive News
ANIX Anixa Biosciences	4.1113 of 5 stars	$3.22 +3.5%	$8.50 +164.0%	-2.5%	$105.81M	$210K	N/A	5	News Coverage
FTLF FitLife Brands	4.6306 of 5 stars	$11.10 +2.2%	$21.50 +93.7%	-14.1%	$101.99M	$81.46M	18.38	20	News Coverage Positive News Short Interest Decrease
AADI Aadi Bioscience	N/A	$3.96 -4.6%	N/A	+107.9%	$97.80M	$25.07M	N/A	40	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CPHI) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

China Pharma (CPHI) Competitors

CPHI vs. BDTX, ANIX, FTLF, AADI, and SXTC

How does China Pharma compare to Black Diamond Therapeutics?

Summary

How does China Pharma compare to Anixa Biosciences?

Summary

How does China Pharma compare to FitLife Brands?

Summary

How does China Pharma compare to Aadi Bioscience?

Summary

How does China Pharma compare to China SXT Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI vs. The Competition

China Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

China Pharma (CPHI) Competitors

CPHI vs. BDTX, ANIX, FTLF, AADI, and SXTC

How does China Pharma compare to Black Diamond Therapeutics?

Which has more volatility and risk, CPHI or BDTX?

Do institutionals & insiders have more ownership in CPHI or BDTX?

Is CPHI or BDTX more profitable?

Which has higher valuation & earnings, CPHI or BDTX?

Do analysts recommend CPHI or BDTX?

Does the media prefer CPHI or BDTX?

Summary

How does China Pharma compare to Anixa Biosciences?

Which has more volatility & risk, CPHI or ANIX?

Is CPHI or ANIX more profitable?

Do analysts recommend CPHI or ANIX?

Does the media refer more to CPHI or ANIX?

Which has higher earnings and valuation, CPHI or ANIX?

Do institutionals and insiders believe in CPHI or ANIX?

Summary

How does China Pharma compare to FitLife Brands?

Do analysts recommend FTLF or CPHI?

Do institutionals & insiders believe in FTLF or CPHI?

Which has more volatility and risk, FTLF or CPHI?

Is FTLF or CPHI more profitable?

Which has better earnings and valuation, FTLF or CPHI?

Does the media prefer FTLF or CPHI?

Summary

How does China Pharma compare to Aadi Bioscience?

Do institutionals & insiders hold more shares of AADI or CPHI?

Which has stronger valuation and earnings, AADI or CPHI?

Is AADI or CPHI more profitable?

Does the media prefer AADI or CPHI?

Which has more volatility and risk, AADI or CPHI?

Summary

How does China Pharma compare to China SXT Pharmaceuticals?

Does the media favor SXTC or CPHI?

Is SXTC or CPHI more profitable?

Which has higher earnings and valuation, SXTC or CPHI?

Do institutionals & insiders hold more shares of SXTC or CPHI?

Do analysts rate SXTC or CPHI?

Which has more risk & volatility, SXTC or CPHI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI vs. The Competition

China Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools